英联邦药物管理署（ＭＣＡ）已拒绝了 Ｇｌａｘｏ Ｗｅｌｌｃｏｍｅ关于再度引进糖尿病治疗药曲格列酮（ｔｒｏｇｌｉｔａｚｏｎｅ）的申请。 该产品在开始使用后不久就于１９９７年１２月在英联邦暂停使用，同期在美国和日本发生了相当数量的对肝损害的病例。在使用者被提醒肝 The Commonwealth Drug Administration (MCA) has rejected Glaxo Wellcome’s request to reintroduce the diabetic drug troglitazone. The product was temporarily suspended in the Commonwealth in December 1997 shortly after its initial use, with significant amounts of liver damage occurring in the United States and Japan over the same period. The user is reminded of the liver